tirzepatide uses and side effects vs. Semaglutide: What You Should Know Tirzepatide vs. Semaglutide: Which Is
Description
The SURMOUNT-1 trial showed that FDA-approved tirzepatide produced average weight loss of 15% at 5mg, 19.5% at 10mg, and 20.9% at 15mg over 72 weeks
Others make early progress at 5 mg and then plateau
CMS launched the BALANCE model in May 2026, enabling Medicaid coverage of GLP-1 medications for qualifying beneficiaries in participating states
Tirzepatide should be discontinued if pancreatitis is suspected, and patients should be educated to recognize symptoms including severe, persistent abdominal pain that may radiate to the back
Walking, light yoga, stretching, mobility work, or easy cycling are all fine
